66 related articles for article (PubMed ID: 8644040)
1. [The effect of micronized phenofibrate on the lipoproteins of the blood plasma at different initial lipid levels].
Perova NV; Ozerova IN; Kalinina AM; Pavlova LI; Olfer'ev AM; Mel'kina OE; Golubev MA; Oganov RG
Ter Arkh; 1996; 68(1):71-6. PubMed ID: 8644040
[TBL] [Abstract][Full Text] [Related]
2. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of patients with hypertriglyceridemia].
Rozhkova TA; Kukharchuk VV; Titov VN; Iarovaia EB; Kotova LA; Malyshev PP; Ameliushkina VA
Ter Arkh; 2009; 81(9):29-33. PubMed ID: 19827649
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
5. [Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias].
Vaverková H; Novotný D; Ficker L
Vnitr Lek; 1996 Apr; 42(4):239-45. PubMed ID: 8693709
[TBL] [Abstract][Full Text] [Related]
6. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
Zhu J; Ye P
Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Farnier M; Freeman MW; Macdonell G; Perevozskaya I; Davies MJ; Mitchel YB; Gumbiner B;
Eur Heart J; 2005 May; 26(9):897-905. PubMed ID: 15781429
[TBL] [Abstract][Full Text] [Related]
8. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
9. [Pleiotropic effect of the micronized fenofibrate: the reduction of plasma chlamydia pneumoniae antibody levels in patients with coronary artery disease].
Márk L; Márki-Zay J; Orosz I; Kondacs A; Erdei F; Katona A
Orv Hetil; 2003 Apr; 144(16):765-8. PubMed ID: 12778627
[TBL] [Abstract][Full Text] [Related]
10. [Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].
Zeman M; Zák A; Vecka M; Tvrzická E; Písaríková A; Stanková B
Cas Lek Cesk; 2005; 144(11):737-41. PubMed ID: 16335699
[TBL] [Abstract][Full Text] [Related]
11. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
[TBL] [Abstract][Full Text] [Related]
12. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
13. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
14. [A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia].
Kukharchuk VV; Rozhkova TA; Kotova LA; Tvorogova MG; Semenova OA
Ter Arkh; 1996; 68(6):58-61. PubMed ID: 8771689
[TBL] [Abstract][Full Text] [Related]
15. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
Dobiásová M; Frohlich J
Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517
[TBL] [Abstract][Full Text] [Related]
16. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb.
Madej A; Okopien B; Kowalski J; Zielinski M; Wysocki J; Szygula B; Kalina Z; Herman ZS
Int J Clin Pharmacol Ther; 1998 Jun; 36(6):345-9. PubMed ID: 9660044
[TBL] [Abstract][Full Text] [Related]
17. The effect of pirozadil on plasma lipids and lipoproteins in 1185 hyperlipidaemic subjects. Multicentre study in general practice in Spain.
Tapounet R; Marti Ragué I
Drugs Exp Clin Res; 1987; 13(7):447-50. PubMed ID: 3652931
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
McKenney JM; Farnier M; Lo KW; Bays HE; Perevozkaya I; Carlson G; Davies MJ; Mitchel YB; Gumbiner B
J Am Coll Cardiol; 2006 Apr; 47(8):1584-7. PubMed ID: 16630994
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
Farnier M; Roth E; Gil-Extremera B; Mendez GF; Macdonell G; Hamlin C; Perevozskaya I; Davies MJ; Kush D; Mitchel YB;
Am Heart J; 2007 Feb; 153(2):335.e1-8. PubMed ID: 17239698
[TBL] [Abstract][Full Text] [Related]
20. [level of 7alpha-hydroxycholesterol in blood plasma as an indicator of cholesterol catabolism in hyperlipidemia and with hypolipidemic therapy].
Poliakova ED; Ivanova TN; Voshchinnikov EI; Olfer'ev AM; Perova NV
Vopr Med Khim; 2000; 46(2):168-75. PubMed ID: 10885038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
